These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3033258)

  • 21. Distinct inhibition by non-peptide and peptide arginine vasopressin antagonists of vasopressin-induced activation of mitogen-activated protein kinase in cultured rat vascular smooth muscle cells.
    Okada K; Sasaki R; Ishikawa S; Saito T
    Biochem Biophys Res Commun; 1994 Apr; 200(2):1155-60. PubMed ID: 8179597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Properties of [3H]1-desamino-8-D-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney.
    Marchingo AJ; Abrahams JM; Woodcock EA; Smith AI; Mendelsohn FA; Johnston CI
    Endocrinology; 1988 Apr; 122(4):1328-36. PubMed ID: 2964362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure activity relationship studies with C-terminal fragments of vasopressin and oxytocin on avoidance behaviors of rats.
    de Wied D; Gaffori O; Burbach JP; Kovács GL; van Ree JM
    J Pharmacol Exp Ther; 1987 Apr; 241(1):268-74. PubMed ID: 3572787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Difference between male and female rats in vasopressor response to arginine vasopressin.
    László FA; Varga C; Papp A; Pávó I; Fahrenholz F
    Acta Physiol Hung; 1993; 81(2):137-45. PubMed ID: 8197870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin and analogs inhibit endogenous synaptic plasma membrane protein phosphorylation in vitro.
    Dokas LA; Zwiers H; Coy DH; Gispen WH
    Eur J Pharmacol; 1983 Mar; 88(2-3):185-93. PubMed ID: 6133768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.
    Rivier C; Rivier J; Mormede P; Vale W
    Endocrinology; 1984 Sep; 115(3):882-6. PubMed ID: 6086290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat.
    Nagahama S; Chen YF; Lindheimer MD; Oparil S
    J Pharmacol Exp Ther; 1986 Nov; 239(2):426-32. PubMed ID: 3772802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of B-50 phosphorylation and polyphosphoinositide metabolism in synaptic plasma membranes by protein kinase C, phorbol diesters and ACTH.
    De Graan PN; Dekker LV; De Wit M; Schrama LH; Gispen WH
    J Recept Res; 1988; 8(1-4):345-61. PubMed ID: 2838621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arginine vasopressin prevents amyloid beta protein-induced impairment of long-term potentiation in rat hippocampus in vivo.
    Jing W; Guo F; Cheng L; Zhang JF; Qi JS
    Neurosci Lett; 2009 Feb; 450(3):306-10. PubMed ID: 19059464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vasopressin-mediated protein phosphorylation in intact toad urinary bladder.
    Konieczkowski M; Rudolph SA
    J Pharmacol Exp Ther; 1985 Aug; 234(2):515-21. PubMed ID: 2991503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of human platelet vasopressin receptors.
    Thibonnier M; Roberts JM
    J Clin Invest; 1985 Nov; 76(5):1857-64. PubMed ID: 2997293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel radiolabeled vasopressin antagonist: [3H-Phe]-desGlyd(CH2)5D-Tyr(Et)VAVP, [3H]-SK&F 101926.
    Stassen FL; Heckman G; Schmidt D; Nambi P; Aiyar N; Landvatter S; Crooke ST
    Mol Pharmacol; 1987 Mar; 31(3):267-72. PubMed ID: 2951585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arginine vasopressin and adrenocorticotropin release: correlation between binding characteristics and biological activity in anterior pituitary dispersed cells.
    Spinedi E; Negro-Vilar A
    Endocrinology; 1984 Jun; 114(6):2247-51. PubMed ID: 6327240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two classes of arginine vasopressin binding sites on rat brain membranes.
    Junig JT; Abood LG; Skrobala AM
    Neurochem Res; 1985 Sep; 10(9):1187-202. PubMed ID: 4058655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct relation of long-term synaptic potentiation to phosphorylation of membrane protein F1, a substrate for membrane protein kinase C.
    Lovinger DM; Colley PA; Akers RF; Nelson RB; Routtenberg A
    Brain Res; 1986 Dec; 399(2):205-11. PubMed ID: 3828760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of 3H-AVP binding sites in particulate preparations of rat brain.
    Pearlmutter AF; Costantini MG; Loeser B
    Peptides; 1983; 4(3):335-41. PubMed ID: 6415623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arginine-vasopressin binding sites in rat brain: a quantitative autoradiographic study.
    Biegon A; Terlou M; Voorhuis TD; de Kloet ER
    Neurosci Lett; 1984 Feb; 44(3):229-34. PubMed ID: 6728291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a 52-kDa phosphoprotein from synaptic plasma membranes related to long-term potentiation and the major coated vesicle phosphoprotein.
    Schrama LH; de Graan PN; Zwiers H; Gispen WH
    J Neurochem; 1986 Dec; 47(6):1843-8. PubMed ID: 3095494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term facilitation of social recognition in rats by vasopressin related peptides: a structure-activity study.
    Popik P; Van Ree JM
    Life Sci; 1992; 50(8):567-72. PubMed ID: 1736027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcellular localization and characterization of vasopressin binding sites in the ventral septal area, lateral septum, and hippocampus of the rat brain.
    Poulin P; Lederis K; Pittman QJ
    J Neurochem; 1988 Mar; 50(3):889-98. PubMed ID: 3339362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.